Revelation Biosciences (REVB) Competitors

Revelation Biosciences logo
$3.97 +0.09 (+2.27%)
Closing price 03:58 PM Eastern
Extended Trading
$3.93 -0.04 (-1.03%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

REVB vs. GDTC, CMMB, INAB, PHIO, and ALVR

Should you buy Revelation Biosciences stock or one of its competitors? Revelation Biosciences's main competitors and comparable companies include CytoMed Therapeutics (GDTC), Chemomab Therapeutics (CMMB), IN8bio (INAB), Phio Pharmaceuticals (PHIO), and AlloVir (ALVR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Revelation Biosciences compare to CytoMed Therapeutics?

Revelation Biosciences (NASDAQ:REVB) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

CytoMed Therapeutics' return on equity of 0.00% beat Revelation Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Revelation BiosciencesN/A -124.23% -98.96%
CytoMed Therapeutics N/A N/A N/A

12.8% of Revelation Biosciences shares are held by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are held by institutional investors. 4.8% of Revelation Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

CytoMed Therapeutics has higher revenue and earnings than Revelation Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revelation BiosciencesN/AN/A-$8.91M-$42.52N/A
CytoMed Therapeutics$250K37.05-$3.10MN/AN/A

In the previous week, Revelation Biosciences had 10 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 10 mentions for Revelation Biosciences and 0 mentions for CytoMed Therapeutics. CytoMed Therapeutics' average media sentiment score of 1.82 beat Revelation Biosciences' score of 0.46 indicating that CytoMed Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Revelation Biosciences Neutral
CytoMed Therapeutics Very Positive

CytoMed Therapeutics has a consensus target price of $4.16, suggesting a potential upside of 431.29%. Given CytoMed Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CytoMed Therapeutics is more favorable than Revelation Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revelation Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
CytoMed Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Revelation Biosciences has a beta of -0.13, meaning that its share price is 113% less volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market.

Summary

CytoMed Therapeutics beats Revelation Biosciences on 9 of the 12 factors compared between the two stocks.

How does Revelation Biosciences compare to Chemomab Therapeutics?

Chemomab Therapeutics (NASDAQ:CMMB) and Revelation Biosciences (NASDAQ:REVB) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chemomab TherapeuticsN/AN/A-$8.99M-$2.13N/A
Revelation BiosciencesN/AN/A-$8.91M-$42.52N/A

In the previous week, Revelation Biosciences had 10 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 10 mentions for Revelation Biosciences and 0 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 1.39 beat Revelation Biosciences' score of 0.46 indicating that Chemomab Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Chemomab Therapeutics Positive
Revelation Biosciences Neutral

Chemomab Therapeutics' return on equity of -92.14% beat Revelation Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Chemomab TherapeuticsN/A -92.14% -82.05%
Revelation Biosciences N/A -124.23%-98.96%

Chemomab Therapeutics has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market. Comparatively, Revelation Biosciences has a beta of -0.13, indicating that its share price is 113% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Chemomab Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Revelation Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

46.1% of Chemomab Therapeutics shares are held by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by insiders. Comparatively, 4.8% of Revelation Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Chemomab Therapeutics beats Revelation Biosciences on 7 of the 10 factors compared between the two stocks.

How does Revelation Biosciences compare to IN8bio?

IN8bio (NASDAQ:INAB) and Revelation Biosciences (NASDAQ:REVB) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

In the previous week, Revelation Biosciences had 9 more articles in the media than IN8bio. MarketBeat recorded 10 mentions for Revelation Biosciences and 1 mentions for IN8bio. IN8bio's average media sentiment score of 0.71 beat Revelation Biosciences' score of 0.46 indicating that IN8bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IN8bio
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Revelation Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

IN8bio is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IN8bioN/AN/A-$19.44M-$1.01N/A
Revelation BiosciencesN/AN/A-$8.91M-$42.52N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IN8bio
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Revelation Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

IN8bio has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, Revelation Biosciences has a beta of -0.13, suggesting that its stock price is 113% less volatile than the broader market.

IN8bio's return on equity of -93.66% beat Revelation Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
IN8bioN/A -93.66% -78.41%
Revelation Biosciences N/A -124.23%-98.96%

92.1% of IN8bio shares are held by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are held by institutional investors. 14.5% of IN8bio shares are held by insiders. Comparatively, 4.8% of Revelation Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

IN8bio beats Revelation Biosciences on 9 of the 12 factors compared between the two stocks.

How does Revelation Biosciences compare to Phio Pharmaceuticals?

Phio Pharmaceuticals (NASDAQ:PHIO) and Revelation Biosciences (NASDAQ:REVB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Phio Pharmaceuticals has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Revelation Biosciences has a beta of -0.13, suggesting that its stock price is 113% less volatile than the broader market.

In the previous week, Revelation Biosciences had 5 more articles in the media than Phio Pharmaceuticals. MarketBeat recorded 10 mentions for Revelation Biosciences and 5 mentions for Phio Pharmaceuticals. Phio Pharmaceuticals' average media sentiment score of 1.21 beat Revelation Biosciences' score of 0.46 indicating that Phio Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Phio Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Revelation Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Phio Pharmaceuticals currently has a consensus price target of $14.00, suggesting a potential upside of 1,852.04%. Given Phio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Phio Pharmaceuticals is more favorable than Revelation Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Phio Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Revelation Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

57.3% of Phio Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are owned by institutional investors. 3.5% of Phio Pharmaceuticals shares are owned by insiders. Comparatively, 4.8% of Revelation Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Phio PharmaceuticalsN/AN/A-$8.70M-$1.21N/A
Revelation BiosciencesN/AN/A-$8.91M-$42.52N/A

Phio Pharmaceuticals' return on equity of -101.48% beat Revelation Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Phio PharmaceuticalsN/A -101.48% -90.96%
Revelation Biosciences N/A -124.23%-98.96%

Summary

Phio Pharmaceuticals beats Revelation Biosciences on 10 of the 12 factors compared between the two stocks.

How does Revelation Biosciences compare to AlloVir?

Revelation Biosciences (NASDAQ:REVB) and AlloVir (NASDAQ:ALVR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

AlloVir's return on equity of -71.03% beat Revelation Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Revelation BiosciencesN/A -124.23% -98.96%
AlloVir N/A -71.03%-61.27%

Revelation Biosciences has a beta of -0.13, suggesting that its share price is 113% less volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market.

Revelation Biosciences is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revelation BiosciencesN/AN/A-$8.91M-$42.52N/A
AlloVirN/AN/A-$190.42M-$20.23N/A

12.8% of Revelation Biosciences shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 4.8% of Revelation Biosciences shares are held by insiders. Comparatively, 32.1% of AlloVir shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revelation Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
AlloVir
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Revelation Biosciences had 9 more articles in the media than AlloVir. MarketBeat recorded 10 mentions for Revelation Biosciences and 1 mentions for AlloVir. AlloVir's average media sentiment score of 0.67 beat Revelation Biosciences' score of 0.46 indicating that AlloVir is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Revelation Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
AlloVir
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

AlloVir beats Revelation Biosciences on 8 of the 11 factors compared between the two stocks.

Get Revelation Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for REVB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding REVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

REVB vs. The Competition

MetricRevelation BiosciencesBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2.65M$4.03B$7.72B$11.68B
Dividend YieldN/A3.63%2.47%4.51%
P/E Ratio-0.0925.9032.4827.27
Price / SalesN/A15.668.385.63
Price / CashN/A22.7220.8521.62
Price / Book0.374.164.443.72
Net Income-$8.91M-$23.99M$3.51B$394.03M
7 Day Performance-4.41%-8.45%-6.54%-6.07%
1 Month Performance16.95%-6.55%-4.93%-7.38%
1 Year Performance-83.52%-6.56%-1.68%-7.46%

Revelation Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
REVB
Revelation Biosciences
0.7758 of 5 stars
$3.97
+2.3%
N/A-84.0%$2.65MN/AN/A9
GDTC
CytoMed Therapeutics
2.2243 of 5 stars
$0.84
+0.5%
$4.16
+395.2%
-60.5%$9.89M$250KN/A42
CMMB
Chemomab Therapeutics
0.9958 of 5 stars
$1.35
+0.4%
N/A-36.9%$9.75MN/AN/A12
INAB
IN8bio
1.3522 of 5 stars
$0.87
-3.1%
N/A-48.4%$9.73MN/AN/A18
PHIO
Phio Pharmaceuticals
4.3945 of 5 stars
$0.81
-0.1%
$14.00
+1,621.6%
-45.7%$9.73MN/AN/A6

Related Companies and Tools


This page (NASDAQ:REVB) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners